The TNL Mediagene (TNMG) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. TNL Mediagene files reports on Form 6-K under the Securities Exchange Act of 1934, furnishing press releases, transaction documents and corporate updates that explain key developments in its digital media and data business.
Recent Form 6-K filings include explanations of Nasdaq listing status and compliance with the minimum bid price rule, details of a 1-for-20 share consolidation of ordinary shares, and descriptions of financing arrangements such as senior convertible notes and an equity line of credit. Other filings furnish press releases related to unaudited financial results, annual general meeting outcomes, amendments to corporate documents, and information about board changes and director appointments.
For investors analyzing TNL Mediagene’s capital structure, these filings outline terms of convertible notes, warrants and equity purchase agreements, as well as the company’s interactions with the Nasdaq Hearings Panel. They also incorporate press releases that describe operational initiatives, including AI-driven content infrastructure, content licensing partnerships and business unit performance, giving additional context to the company’s strategic direction.
On Stock Titan, each filing is accompanied by AI-powered summaries designed to highlight the main points of long-form documents, helping readers quickly understand what a particular Form 6-K covers and why it may matter for TNMG stock. Users can monitor new filings as they are retrieved from EDGAR, review historical disclosures, and connect regulatory information with the company’s broader narrative in digital media, advertising technology and e-commerce.
TNL Mediagene (TNMG) completed a $6.25 million investment from Vector Advisory Partners LLC on October 30, 2026, issuing Series A and Series B convertible preferred shares. Vector paid $1.5 million at signing and $4.75 million at closing, including direct payments to holders of certain outstanding convertible notes and transaction service providers. At Vector’s direction, 938,257 Series A and 2,816,647 Series B shares were issued to designees Ka Lun To and Chi Ching Hung in approximately equal proportions. Remaining proceeds after payoffs and approved transaction expenses will be retained as permanent equity and working capital, including an initial operating-transition reserve of at least $750,000 unless Vector otherwise approves; up to $800,000 may be designated after closing for an issuer-repurchase reserve, subject to further board approval and applicable legal and Nasdaq requirements.
Before required shareholder, Nasdaq, Cayman Islands and other approvals, Series A represents approximately 19.99% of fully diluted ordinary shares on an as-converted basis; Series B cannot convert until applicable approvals are obtained and effective. Following approvals, the preferred shares are expected to represent approximately 80% on that basis, resulting in a change of control. Shing Hei Lee, Vector’s designee, was appointed a director effective at closing; the board has five directors.
TNL Mediagene (TNMG) completed the sale of all issued and outstanding shares of its Japanese holding company to MI Company on October 30, 2026, for aggregate consideration of $5.5 million. At closing, MI Company paid or satisfied the purchase price with approximately $3.85 million in cash, approximately $0.15 million through set-off of net intercompany debt liabilities, and $1.5 million through assumption, discharge, cancellation or other extinguishment of indebtedness under Company promissory notes. Consideration is subject to adjustment based on changes in net intercompany debt liabilities from $612,064 as of July 31, 2026, and to set-off; the aggregate amount of adjustments and set-off is capped at $500,000.
The holding company held, directly or indirectly, Mediagene Inc. and Infobahn Inc. MI Company was formed as the acquisition vehicle for an investor group led by Motoko Imada, TNMG’s former CEO and director. A special committee of disinterested, independent directors reviewed and negotiated the sale, and the board approved it on the committee’s recommendation. At closing, Imada and Hiroto Kobayashi resigned from the board; Imada, CFO Hiroyuki Terao and Chief Governance Officer Aya Miyake also resigned from their positions. TNMG continues to operate in Taiwan and believes stockholders’ equity exceeds Nasdaq’s $2.5 million minimum, stating it has demonstrated compliance.
TNL Mediagene entered into an agreement for Vector Advisory Partners LLC to purchase newly authorized Series A and Series B convertible preferred shares for an aggregate purchase price of $6.25 million. Vector paid a $1.5 million signing payment, credited dollar-for-dollar against the purchase price; the remaining $4.75 million is due at closing. The company expects to use proceeds for approved debt repayments and transaction expenses, retaining the balance as permanent equity and working capital. This includes an initial operating-transition reserve of at least $750,000 unless Vector otherwise approves; up to $800,000 may be designated after closing for an issuer-repurchase reserve, subject to further board approval and applicable legal and Nasdaq requirements.
At closing, the company expects to issue approximately 938,257 Series A and 2,816,647 Series B preferred shares, each with an original issue price of approximately $1.66449 per share. Before required shareholder, Nasdaq, Cayman Islands and other approvals, Series A is expected to represent approximately 19.99% of fully diluted ordinary shares on an as-converted basis; Series B cannot convert until applicable approvals are obtained and effective. Following those approvals, both series are expected to represent approximately 80%, resulting in a change of control. No ordinary shares will be issued at closing; closing is expected no later than the tenth calendar day following the agreement’s effective date, subject to specified conditions.
TNL Mediagene (TNMG) regained compliance with Nasdaq’s minimum bid price requirement, Nasdaq confirmed in a letter dated October 14, 2026. Under the Nasdaq Hearings Panel’s August 23, 2026 decision, the company’s ordinary shares will continue to be listed and traded on The Nasdaq Capital Market during an exception period, subject to the decision’s terms.
The company remains non-compliant with Nasdaq’s stockholders’ equity requirement, which requires at least $2.5 million in stockholders’ equity. TNL Mediagene must demonstrate compliance on or before October 30, 2026, and the Panel will review any compliance submission. The company intends to take all steps necessary to meet the requirement by that deadline, but there can be no assurance it will do so. If it fails to demonstrate compliance by the deadline or otherwise fails to satisfy the decision’s terms, its securities will be subject to delisting from Nasdaq.
TNL Mediagene (symbol: TNMG) is the issuer of record for a Form 6-K filing submitted to the SEC.
TNL Mediagene (TNMG) has approved and is implementing a 1-for-8 share consolidationSeptember 8, 2026 under the same ticker, with a new CUSIP.
Every eight issued and outstanding ordinary shares will be combined into one, with no fractional shares issued and any fractions rounded up to the nearest whole share. This will reduce the number of outstanding ordinary shares from 6,084,581 to approximately 760,573, based on shares outstanding as of September 2, 2026. The consolidation is intended to increase the trading price of the shares to assist in regaining compliance with Nasdaq’s $1.00 minimum bid price requirement and to potentially broaden institutional investor interest. Related warrants, equity awards and other equity instruments will have their exercise or conversion prices adjusted proportionally.
TNL Mediagene (TNMG) reports that the Nasdaq Hearings Panel has granted its request for continued listing on The Nasdaq Capital Market, subject to meeting specified conditions during an exception period. The decision follows an August 4, 2026 hearing where the company presented a plan to regain compliance with Nasdaq’s Bid Price Rule and Equity Rule.
The company’s ordinary shares will continue trading under symbol TNMG while it works to regain and maintain compliance, and it must promptly notify Nasdaq of any significant events affecting its status. The Panel may reconsider the exception if circumstances change, and TNL Mediagene cautions that there is no assurance it will satisfy the conditions; failure would result in delisting of its securities from Nasdaq.
TNL Mediagene reported that its Board of Directors has formed a special committee of independent directors to lead an evaluation of potential strategic transactions and alternatives. The committee consists of Priscilla Han (Chair), Lauren Zalaznick, and Naoko Okumoto.
The special committee is authorized to review, evaluate and, as appropriate, negotiate and make recommendations on options that may include a financing, recapitalization, merger, business combination, share issuance, disposition, or continuing the current operations. It has engaged Greenberg Traurig, LLP as independent legal counsel and Imperial Capital, LLC as independent financial advisor, with Imperial Capital tasked to identify and evaluate transactions aimed at maximizing shareholder value. Management will continue operating the business and support the process when requested. No definitive course of action has been determined, and there is no assurance that any transaction will occur.
TNL Mediagene has fully repaid its senior convertible notes issued to 3i, LP and mutually terminated the related securities purchase agreement. The initial note had a principal amount of $4,722,222 and was repaid on November 11, 2025. The second note had a principal amount of $1,666,667 with accrued interest of $150,000.03 and was fully repaid on July 8, 2026, including repayments made in shares totaling 3,381,700 ordinary shares.
On July 23, 2026, the company and 3i entered into a Termination Agreement that extinguishes all obligations under the note facility and related documents and provides mutual releases between the parties. The company states that no convertible notes remain outstanding under this facility, substantially reducing convertible-instrument-related dilution and overhang on its ordinary shares. The 3i warrant issued in December 2025 and the ordinary share purchase agreement with Tumim Stone Capital, LLC remain in effect, and 3i retains a right to participate for up to 25% of certain new financings for one year.
TNL Mediagene reports that Nasdaq staff has determined its securities are subject to delisting from The Nasdaq Capital Market. Nasdaq cited two key issues: the company’s ordinary share closing bid price stayed below $1.00 for 30 consecutive business days from May 7, 2026 through June 18, 2026, and previously disclosed non-compliance with the $2,500,000 minimum stockholders’ equity requirement.
Because TNL Mediagene completed a reverse stock split within the prior year, it is not eligible for an additional compliance period under Listing Rule 5810(c)(3)(A)(iv). The company is already under a one-year Discretionary Panel Monitor and now plans to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay any suspension and Form 25-NSE filing. Its shares will continue trading under “TNMG” while the appeal is pending, but there is no assurance the company will regain compliance or maintain its Nasdaq listing.